Insmed Incorporated (NASDAQ:INSM) is Acuta Capital Partners LLC’s 4th Largest Position

Acuta Capital Partners LLC raised its position in Insmed Incorporated (NASDAQ:INSM) by 49.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 107,500 shares of the biopharmaceutical company’s stock after purchasing an additional 35,400 shares during the period. Insmed accounts for 6.4% of Acuta Capital Partners LLC’s investment portfolio, making the stock its 4th largest holding. Acuta Capital Partners LLC owned approximately 0.06% of Insmed worth $7,848,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. V Square Quantitative Management LLC purchased a new position in Insmed in the third quarter valued at $30,000. GAMMA Investing LLC increased its holdings in shares of Insmed by 71.3% in the 3rd quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 224 shares during the last quarter. First Horizon Advisors Inc. raised its position in shares of Insmed by 83.4% during the 2nd quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 287 shares in the last quarter. Exchange Traded Concepts LLC lifted its stake in Insmed by 522.5% during the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 627 shares during the last quarter. Finally, CWM LLC boosted its holdings in Insmed by 11.0% in the second quarter. CWM LLC now owns 1,570 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 155 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on INSM shares. Truist Financial reissued a “buy” rating and set a $105.00 price objective (up previously from $100.00) on shares of Insmed in a report on Friday, November 1st. Stifel Nicolaus upped their price objective on shares of Insmed from $74.00 to $88.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Bank of America lifted their target price on Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. HC Wainwright reissued a “buy” rating and issued a $90.00 target price on shares of Insmed in a report on Friday, November 1st. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Insmed in a research note on Monday, September 9th. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Insmed has a consensus rating of “Moderate Buy” and a consensus target price of $83.67.

Insider Activity at Insmed

In related news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $71.50, for a total value of $2,686,612.50. Following the completion of the sale, the insider now owns 100,100 shares in the company, valued at $7,157,150. This trade represents a 27.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Michael Alexander Smith sold 27,871 shares of the company’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $74.35, for a total transaction of $2,072,208.85. Following the transaction, the insider now owns 67,856 shares in the company, valued at $5,045,093.60. The trade was a 29.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 78,882 shares of company stock worth $5,765,446 over the last three months. 4.60% of the stock is currently owned by corporate insiders.

Insmed Stock Up 0.3 %

Shares of NASDAQ:INSM opened at $75.88 on Thursday. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $80.53. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The firm’s 50-day simple moving average is $72.16 and its 200-day simple moving average is $67.34. The company has a market cap of $13.57 billion, a price-to-earnings ratio of -13.67 and a beta of 1.12.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The business had revenue of $93.40 million during the quarter, compared to the consensus estimate of $93.36 million. During the same quarter in the previous year, the company earned ($1.10) earnings per share. The company’s quarterly revenue was up 18.1% compared to the same quarter last year. As a group, equities research analysts predict that Insmed Incorporated will post -5.42 earnings per share for the current year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.